Pharmacokinetic drug evaluation of co-packaged sulbactam for injection and durlobactam for injection for the treatment of Acinetobacter baumannii-calcoaceticus complex in HABP/VABP

Introduction Carbapenem-resistant Acinetobacter baumannii (CRAB) is an urgent-priority pathogen that is associated with high mortality and leaves clinicians reliant on nephrotoxic salvage regimens. Sulbactam/durlobactam (S/D) pairs sulbactam's intrinsic anti-Acinetobacter activity with the broad Ambler class A/C/D β-lactamase inhibitor durlobactam, creating the first agent targeting CRAB.